These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30568023)

  • 1. Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs.
    Layton JL; Lewis B; Ryan C; Beer TM; Sartor O
    Oncologist; 2019 Mar; 24(3):291-292. PubMed ID: 30568023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy.
    Bekker CL; Melis EJ; Egberts ACG; Bouvy ML; Gardarsdottir H; van den Bemt BJF
    Res Social Adm Pharm; 2019 Jan; 15(1):100-105. PubMed ID: 29610051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs: The ROAD Study.
    Smale EM; van den Bemt BJF; Heerdink ER; Desar IME; Egberts TCG; Bekker CL;
    JAMA Oncol; 2024 Jan; 10(1):87-94. PubMed ID: 37971730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.
    Betcher J; Dow E; Khera N
    Curr Hematol Malig Rep; 2016 Aug; 11(4):288-94. PubMed ID: 27086140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines.
    Matti N; Delon C; Rybarczyk-Vigouret MC; Khan GM; Beck M; Michel B
    Int J Clin Pharm; 2020 Oct; 42(5):1311-1318. PubMed ID: 32857257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs.
    Lam M; Olivier T; Haslam A; Tuia J; Prasad V
    JAMA Oncol; 2023 Sep; 9(9):1238-1244. PubMed ID: 37471095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic.
    McNabb L; Metrot E; Ferrington M; Sunderland B; Parsons R; Copeland TS; Corscadden S; Tong S; Czarniak P
    PLoS One; 2024; 19(6):e0304011. PubMed ID: 38870231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and measurement of adherence to oral antineoplastic agents.
    Spoelstra SL; Given CW
    Semin Oncol Nurs; 2011 May; 27(2):116-32. PubMed ID: 21514481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste.
    Looney B; Crumb J; White S; Jones G; Moore RP; Choi L; Zuckerman AD; Whelchel K
    J Manag Care Spec Pharm; 2024 May; 30(5):465-474. PubMed ID: 38701029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of oral agents as antineoplastic treatments.
    Given BA; Spoelstra SL; Grant M
    Semin Oncol Nurs; 2011 May; 27(2):93-103. PubMed ID: 21514479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.
    Shih YT; Xu Y; Zhao H; Schrag D; Yao J
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34350376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.
    Deng J; Brar SS; Lesko LJ
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):455-464. PubMed ID: 29197167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of antineoplastic agents in pregnancy.
    Wiebe VJ; Sipila PE
    Crit Rev Oncol Hematol; 1994 Apr; 16(2):75-112. PubMed ID: 8068213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of microtubule targeting agents with other antineoplastics for cancer treatment.
    Liang T; Lu L; Song X; Qi J; Wang J
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188777. PubMed ID: 35963551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
    Shaheen PE; Stadler W; Elson P; Knox J; Winquist E; Bukowski RM
    Invest New Drugs; 2005 Dec; 23(6):577-81. PubMed ID: 16034517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food and oral antineoplastics: more than meets the eye.
    Jain RK; Brar SS; Lesko LJ
    Clin Cancer Res; 2010 Sep; 16(17):4305-7. PubMed ID: 20736331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.
    Kim SH; Suh Y; Ah YM; Jun K; Lee JY
    Support Care Cancer; 2020 Aug; 28(8):3617-3626. PubMed ID: 31802250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-office dispensing of oral oncolytics: a continuity of care and cost mitigation model for cancer patients.
    Egerton NJ
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s99-s103. PubMed ID: 27270161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recycling unused medications in hospitals is financially viable and good for the environment.
    Drummond I; Bains R; Dosanjh A; Ladhar S; Tang L; Heidary D; Tejani AM
    Int J Pharm Pract; 2023 Sep; 31(5):562-564. PubMed ID: 37566550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.